Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$27.55−0.49 (-1.75%)
Close on Nov 18, 2026Market cap $2.16BP/E –Yield –
Celldex Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was $1.35M, down 80.3% from the year before. The highest annual figure on record is $12.04M in fiscal 2017.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.35M | -80.3% |
| FY2024 | Dec 31, 2024 | $6.82M | +3.6% |
| FY2023 | Dec 31, 2023 | $6.58M | +191.7% |
| FY2022 | Dec 31, 2022 | $2.26M | -50.4% |
| FY2021 | Dec 31, 2021 | $4.55M | -36.9% |
| FY2020 | Dec 31, 2020 | $7.22M | +107.8% |
| FY2019 | Dec 31, 2019 | $3.47M | -60.7% |
| FY2018 | Dec 31, 2018 | $8.84M | -26.6% |
| FY2017 | Dec 31, 2017 | $12.04M | +132.2% |
| FY2016 | Dec 31, 2016 | $5.19M | – |
See a number that looks wrong?